Stock comparison
Genmab A/S
Xeris Biopharma Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
XERS
Xeris Biopharma Holdings
Market cap
$1.07B
Sector
Healthcare
Overall winner
Xeris Biopharma Holdings XERS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | XERS | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 49D | GMAB |
| Benjamin Graham | 64C | 81D | XERS |
| Philip Fisher | 48D | 67C | XERS |
| Peter Lynch | 25F | 86C | XERS |
| Joel Greenblatt | 76B | 54C | GMAB |
| Charlie Munger | 68C | 62D | GMAB |
| Terry Smith | 71C | 56D | GMAB |
Side-by-side metrics
| Metric | GMAB | XERS |
|---|---|---|
| Market cap | $16.5B | $1.07B |
| P/E (TTM) | 6.2x | 92.7x |
| EV/EBIT | 12.0x | 42.3x |
| ROIC (TTM) | 43.78% | 12.84% |
| Gross margin | 93.88% | 81.59% |
| Net margin | 18.23% | 3.81% |
| Revenue CAGR 5y | -18.45% | 55.75% |
| EPS CAGR 5y | -23.48% | - |
| Debt / Equity | 0.1x | 2.9x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 2.9x+97%
- Market cap$16.5Bvs $1.07B+94%
- P/E (TTM)6.2xvs 92.7x+93%
- Net margin18.23%vs 3.81%+79%
XERS leads on
- Revenue CAGR 5y55.75%vs -18.45%+133%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.